<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Teerlink, John R.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Serelaxin as a Novel Treatment for Acute Heart Failure: Results of the RELAX-AHF Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">22-23</style></pages><abstract><style  face="normal" font="default" size="100%">Relaxin, a naturally occurring peptide, is associated with hemodynamic changes as well anti-ischemic, anti-inflammatory, and antifibrotic effects that may offer benefit to patients with acute heart failure (AHF). This article reports the results of the Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure [RELAX-AHF; NCT00520806] trial designed to test the efficacy and safety of serelaxin, a recombinant version of human relaxin-2, in patients with AHF.</style></abstract><number><style face="normal" font="default" size="100%">18</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>